SMMT — Summit Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1599298 ·
Last close
$16.91
Market Cap
$13.49B
52W High
$29.23
52W Low
$12.07
ADV30
7,146,231
Next earnings
2026-10-19
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -220,496,000 | -215,700,000 | 752,185,000 | 419,365,000 | 122,202,000 |
| Mar 2026 | 0 | — | -195,212,000 | -189,424,000 | 647,856,000 | 106,515,000 | 101,924,000 |
| Dec 2025 | 0 | — | -224,875,000 | -219,172,000 | 751,182,000 | 225,266,000 | 92,322,000 |
| Sep 2025 | 0 | — | -234,211,000 | -231,793,000 | 261,729,000 | 238,554,000 | 69,466,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-458,433,000
Investing CF
$-262,570,000
Financing CF
$842,509,000
CapEx
$-1,389,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.12
As of
2026-07-26
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,699,283,000
Inventory
—
Receivables
$557,000
ST Investments
$271,313,000
EBIT TTM
$-866,623,000
Pretax Income TTM
$-856,039,000
Interest Exp TTM
$0
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,094,374,000 | -1,079,586,000 | 751,182,000 | 92,322,000 | 658,860,000 | -322,930,000 |
| Dec 2024 | 0 | -210,977,000 | -221,315,000 | 435,560,000 | 46,812,000 | 388,748,000 | -142,106,000 |
| Dec 2023 | 0 | -88,735,000 | -614,928,000 | 202,949,000 | 125,257,000 | 77,692,000 | -76,760,000 |
| Dec 2022 | 705,000 | -63,621,000 | -78,782,000 | 664,168,000 | 537,514,000 | 126,654,000 | -41,582,000 |
TTM Snapshot
Revenues TTM
$220,000
NetIncome TTM
$-161,820,000
OpCashFlow TTM
$0
Assets (Latest)
$751,182,000
Forward EPS
$-1.20
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $16.00 · spot: $16.91 · call volume: 5,983 · put volume: 353
Expected Move to 2026-11-20:
±$6.07
(35.90%) —
implied range
$10.84 –
$22.98
· ATM straddle on $17.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | $12.86B | $65.80 | — |
| CORT | CORCEPT THERAPEUTICS INC | $12.46B | $115.23 | — |
| ASND | Ascendis Pharma A/S | $14.99B | $227.83 | — |
| AAVXF | Abivax S.A. | $12.13B | $139.00 | — |
| JAZZ | Jazz Pharmaceuticals plc | $15.03B | $231.52 | — |
News headlines (Yahoo Finance, 1h cache)
AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
2026-09-30 15:17 · Yahoo
AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck
2026-09-29 20:55 · Yahoo
AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says
2026-09-29 19:03 · Yahoo
AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology
2026-09-29 17:17 · Yahoo
Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment
2026-09-29 16:07 · Yahoo
Inside the AstraZeneca Deal That Could Send Summit Therapeutics Stock Up 162%
2026-09-29 14:25 · Yahoo
AstraZeneca’s $2 billion Summit stake wins backing from UBS and Jefferies
2026-09-29 12:30 · Yahoo
Premarket movers: FICO sinks while Summit, AAR and CarMax rise
2026-09-29 11:39 · Yahoo
Summit Secures $2 Billion AstraZeneca Investment, Cancer Drug Trial Collaboration
2026-09-29 11:06 · Yahoo
Summit Therapeutics Shares Rise 22% After $2 Billion AstraZeneca Investment
2026-09-29 10:24 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.